BIOMAT Database Logo BIOMAT Database Logo

Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate. 1988

P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Department of Clinical Pharmacology and Therapeutics, Roswell Park Memorial Institute, Buffalo, NY 14263.

A phase I and pharmacokinetic study of a novel lipid-soluble antifolate, 2,4 diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES) has been carried out on two schedules: I--daily x5; II--24-h continuous infusion. In schedule I, doses of 10-90 mg/m2 per day were evaluated. Dose-limiting toxicity was hematologic, but nausea and vomiting, skin rash, diarrhea, anorexia, alopecia, mucositis, and neurotoxicity were also noted. In schedule II, doses of 192 and 240 mg/m2 were evaluated. Dose-limiting toxicity was neurotoxicity, but hematologic toxicity was also marked. Recommended starting doses for phase II studies are 75 mg/m2 per day for 5 days or 192 mg/m2 by continuous infusion for 24 h. Pharmacokinetic studies indicated a beta-phase plasma half-life of 12.4-24 h and a large and variable volume of distribution.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008433 Mathematics The deductive study of shape, quantity, and dependence. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Mathematic
D008838 Microcomputers Small computers using LSI (large-scale integration) microprocessor chips as the CPU (central processing unit) and semiconductor memories for compact, inexpensive storage of program instructions and data. They are smaller and less expensive than minicomputers and are usually built into a dedicated system where they are optimized for a particular application. "Microprocessor" may refer to just the CPU or the entire microcomputer. Computers, Personal,Microprocessors,Computer, Personal,Microcomputer,Microprocessor,Personal Computer,Personal Computers
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate

Related Publications

P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Studies with a new antifolate 2,4-diamino-5-adamantyl-6-methylpyrimidine (DAMP): tissue distribution and disposition of 2,4-diamino-5-adamantyl-6-methylpyrimidine and its metabolite.
April 1978, The Journal of pharmacology and experimental therapeutics,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Comparison of the antitumor activity and toxicity of 2,4-diamino-5-(1-adamantyl)-6-methylpyrimidine and 2,4-diamino-5-(1-adamantyl)-6-ethylpyrimidine.
May 1978, Journal of the National Cancer Institute,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Enzymatic assays for 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline, a promising new "nonclassical" antifolate.
July 1981, Journal of pharmaceutical sciences,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 10. 2,4-Diamino-5-(6-quinolylmethyl)- and -[(tetrahydro-6-quinolyl)methyl]pyrimidine derivatives. Further specificity studies.
August 1989, Journal of medicinal chemistry,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Phase I clinical trial and pharmacology of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF).
January 1981, Cancer chemotherapy and pharmacology,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines.
November 1982, Molecular pharmacology,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Inhibition of metabolism of the 'nonclassical' antifolate, trimetrexate (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline) by drugs containing an imidazole moiety.
January 1985, Pharmacology,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Lipid-soluble inhibitors of dihydrofolate reductase. III: Quantitative thin-layer and high-performance liquid chromatographic methods for measuring plasma concentrations of the antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido-[2,3-d]pyrimidine.
October 1982, Journal of pharmaceutical sciences,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase.
October 1982, Cancer research,
P J Creaven, and S F Zakrzewski, and W R Greco, and S Madajewicz, and A Mittelman, and J E Pontes, and C Karakousis, and H Takita, and A Proefrock
The crystal and molecular structure of the antifolate drug trimethoprim (2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine). A neutron diffraction study.
April 1976, Journal of the American Chemical Society,
Copied contents to your clipboard!